November 18, 2026 | Anktiva, Brian O’Shaughnessy, ImmunityBio, Market Access, Uniphar, launch

Uniphar and ImmunityBio Partner to Support International Operational Launch and Distribution of ANKTIVA® Across Europe, the UK and MENA
[Dublin, 18th November 2026] Uniphar has today announced a strategic partnership with ImmunityBio to support the full European order-to-cash and 3PL services for ANKTIVA® (nogapendekin alfa inbakicept), an innovative immunotherapy indicated for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumours.
Under the partnership, Uniphar has been selected to design, implement and operate a comprehensive order-to-cash, supply chain, storage, distribution, importation and commercial support platform to support the availability and compliant supply of ANKTIVA across Europe.
Through this collaboration, Uniphar will act as an integrated operational partner, providing scalable and compliant infrastructure to support launch readiness and ongoing commercial supply across multiple international markets. The partnership brings together Uniphar’s expertise in complex pharmaceutical distribution, importation, quality oversight, financial services and operational support with ImmunityBio’s innovation in specialist oncology.
ANKTIVA is authorised in combination with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive NMIBC carcinoma in situ, with or without papillary tumours, and has received regulatory authorisations across the United States, United Kingdom, Kingdom of Saudi Arabia and European Union, according to ImmunityBio’s public communications. ImmunityBio has stated that the European Commission granted conditional marketing authorisation for ANKTIVA in combination with BCG in February 2026, covering the 27 EU member states plus Iceland, Liechtenstein and Norway.
For patients with BCG-unresponsive NMIBC, timely access to innovative treatment options remains a significant priority. This partnership establishes a robust operational model designed to support the availability of ANKTIVA across multiple markets, helping healthcare systems and clinicians access a specialist oncology therapy through a compliant and scalable supply platform.
The collaboration also reflects the growing importance of specialist commercialisation and distribution models for high-value, complex therapies. Uniphar’s established international infrastructure across Europe, MENA and other global markets positions the company to support emerging and specialty biopharmaceutical partners seeking to expand access without building extensive in-country operational infrastructure.
“This partnership reinforces Uniphar’s role as a trusted international partner for biotechnology companies bringing highly specialised therapies to patients across complex markets,” said Brian O’Shaughnessy, Chief Commercial Officer at Uniphar. “By combining our regulatory, quality, supply chain, distribution, order-to-cash capabilities, we can support ImmunityBio with a scalable platform that enables launch readiness and ongoing commercial supply for ANKTIVA.”
“Expanding access to ANKTIVA across Europe and the UK is an important step in our mission to bring this innovative immunotherapy to more patients living with BCG-unresponsive non-muscle-invasive bladder cancer,” explained Richard Adcock, President and CEO of ImmunityBio. “Uniphar’s international expertise in pharmaceutical distribution, supply chain management and commercial logistics will help support the compliant, reliable and timely delivery of ANKTIVA across these complex markets. We look forward to working together to advance the availability of ANKTIVA for patients and the healthcare professionals who care for them.”
ENDS
This content was provided by Uniphar